{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:33:25Z","timestamp":1740130405184,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Dose-dense chemotherapy has shown a better prognosis than standard interval chemotherapy in adjuvant settings for high-risk breast cancer. This study aimed to evaluate the efficacy and safety of dose-dense nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide as neoadjuvant chemotherapy for human epidermal growth factor 2 (HER2)-negative operable breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with histologically confirmed stage I\u2013III HER2-negative breast cancer were enrolled in this study. Patients received nanoparticle albumin-bound paclitaxel (260\u00a0mg\/m2) followed by epirubicin (90\u00a0mg\/m2) and cyclophosphamide (600\u00a0mg\/m2) every 2 weeks with pegfilgrastim. The primary endpoint was the pathological complete response rate. Patients also underwent prophylactic management for peripheral neuropathy, which involved a combination of cryotherapy, compression therapy using elastic stockings and medications including goshajinkigan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 55 patients enrolled in this study, 13 (23.6%) achieved pathological complete response, of whom 10\/26 (38.5%) patients had triple-negative disease and 3\/29 (10.3%) had luminal disease. The objective response was observed in 46 (83.6%) patients. Of the 36 patients who were initially planned for mastectomy, 11 (30.6%) underwent breast-conserving surgery after neoadjuvant chemotherapy. The most common grade 3\u20134 adverse events were myalgia (14.5%), fatigue (12.7%) and elevated transaminase levels (9.1%). No patients experienced febrile neutropenia. Eight (14.5%) patients discontinued treatments due to adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad112","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T07:48:25Z","timestamp":1692776905000},"page":"1119-1124","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-0075","authenticated-orcid":false,"given":"Akiko","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Jinno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Naruse","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Isono","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sasajima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"2023120714400761900_ref1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023120714400761900_ref2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2008.20.3133","article-title":"Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer","volume":"27","author":"Untch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023120714400761900_ref3","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","article-title":"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin\/cyclophosphamide followed by paclitaxel +\/\u2212 darbepoetin alfa in primary breast cancer\u2014results at the time of surgery","volume":"22","author":"Untch","year":"2011","journal-title":"Ann Oncol"},{"key":"2023120714400761900_ref4","doi-asserted-by":"crossref","first-page":"e0234058","DOI":"10.1371\/journal.pone.0234058","article-title":"Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer? A meta-analysis of 3,724 patients","volume":"15","author":"Ding","year":"2020","journal-title":"PloS One"},{"key":"2023120714400761900_ref5","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023120714400761900_ref6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023120714400761900_ref7","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1007\/s00520-020-05345-9","article-title":"Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients","volume":"28","author":"Shigematsu","year":"2020","journal-title":"Support Care Cancer"},{"key":"2023120714400761900_ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-016-3977-7","article-title":"Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group","volume":"160","author":"Tsuyuki","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2023120714400761900_ref9","first-page":"4213","article-title":"Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer","volume":"34","author":"Ohno","year":"2014","journal-title":"Anticancer Res"},{"key":"2023120714400761900_ref10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2019.09.011","article-title":"Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial","volume":"48","author":"Ruddy","year":"2019","journal-title":"Breast"},{"key":"2023120714400761900_ref11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"2023120714400761900_ref12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"2023120714400761900_ref13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs. paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023120714400761900_ref14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm-2018-0485","article-title":"Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer","volume":"14","author":"Xie","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"2023120714400761900_ref15","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1056\/NEJMc2006684","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"Reply N Engl J Med"},{"key":"2023120714400761900_ref16","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023120714400761900_ref17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-010-1187-2","article-title":"Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study","volume":"125","author":"Robert","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/12\/1119\/54060646\/hyad112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/12\/1119\/54060646\/hyad112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:30:13Z","timestamp":1701970213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/12\/1119\/7247504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad112","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,22]]}}}